Based on the standard broth microdilution (BMD) method, the MICRONAUT-S ß-Lactamases Detection system is the only broth microdilution based systems that can differentiate between all Ambler class A (ESBL, KPC), class B (MBL), class C (AMP-C) and class D (OXA-48-like) cephalosporinases and/or carbapenemases.
In recent years, there has been an increase worldwide in carbapenem resistance based on type D carbapenemase-producing Enterobacteriaceae (type OXA-48). These secondary, plasmid encoded, type D carbapenemases can be spread horizontally by plasmid transfer, showing a potential for dissemination of high epidemiologic importance. Moreover, the ß-Lactamases resistance determinants are localized on mobile genetic elements (integrons) that are normally associated with additional resistance genes (e.g. aminoglycosides, fluoroquinolones etc.) bearing the high risk for the spread of multi-resistance among clinically relevant pathogens.
The standard plate MICRONAUT-S ß-Lactamases now includes temocillin and ertapenem/meropenem screening concentrations for detection of low-level carbapenem resistance. These modifications improve the sensitivity of the test system for detection of OXA-48-like type D carbapenemases.
The MICRONAUT-S ß-Lactamases plate has an extended concentration range for ESBL (Extended Spectrum ß-Lactamases) and AMP-C (aminopenicillin inactivating cephalosporinase) detection. The drug concentrations of cefepime, cefotaxime, and ceftazidime are increased up to 128 mg/L. Based on the drug concentration ranges, the sensitivity of the ESBL and AMP-C confirmatory assay is raised by the reduction of “out of range” results. In addition, detection and differentiation of clinically relevant carbapenemases (KPC, MBL, OXA-48-like) is carried out by MIC determination of meropenem and different meropenem-inhibitor combinations.
Please contact your local representative for availability in your country.
Not for sale in the USA.